We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Metabolon Acquires Intellectual Property from Cogenics Icoria

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolon Acquires Intellectual Property from Cogenics Icoria"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Metabolon, Inc. has announced the acquisition of intellectual property from Cogenics Icoria, Inc., a subsidiary of Clinical Data, Inc.

The portfolio includes issued and pending patents related to metabolomics methods and data analysis as well as carcinogenicity and toxicity biomarkers. Metabolon now owns all of the metabolomics-related intellectual property formerly owned by Cogenics Icoria.

“The acquisition of this IP estate strengthens our IP position in this field,” said John Ryals, President and CEO of Metabolon. “The methods patents will enhance our leadership position as the world leader in metabolomics analysis. Furthermore, the biochemical biomarker patents will help drive our rapidly-developing diagnostics business.”